Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04243616
Title Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Medical College of Wisconsin

triple-receptor negative breast cancer

Her2-receptor negative breast cancer


Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel

Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.